Pre-diagnostic presentations of Multiple System Atrophy case control study in a primary care dataset

Schrag, Anette; Bohlken, Jens; Kostev, Karel

doi:10.1016/j.parkreldis.2022.02.003

Cited by 10 publications

(5 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although we have no information on comorbidities that could explain these atypical features (eg, smoking could explain the hyposmia, treatment with dopaminergic agonists could explain the hallucinations), these features may either suggest that some of these patients may have been misdiagnosed or that these features are not as infrequent in MSA as previously thought. The latter is supported by research highlighting the fact that cognitive deficits, including memory complains, are prevalent in patients with MSA, 11,12 that some patients with MSA may develop psychosis unrelated to dopaminergic therapies, 13 and that some patients with MSA have mild or moderate hyposmia. [14][15][16] Additional studies in these MSA populations is warranted as the identification of these patients with atypical features may have clinical, therapeutic, and research implications.…”

Section: Discussionmentioning

confidence: 98%

Patient‐Reported Symptoms in the Global Multiple System Atrophy Registry

Palma

Krismer

Meissner

et al. 2022

Movement Disord Clin Pract

View full text Add to dashboard Cite

Background The Global Multiple System Atrophy Registry (GLOMSAR) was established in 2013. It is an online patient‐reported contact registry open and free that relies on self‐reported diagnosis by the patient or caregiver. Objectives To report the demographics of patients enrolled in GLOMSAR and the results of an ancillary online symptom questionnaire. Methods Patients enrolled in GLOMSAR were invited to complete a custom‐designed online questionnaire about disease onset and symptom prevalence. Results At the time of writing, there were 1083 participants in GLOMSAR, of which 33% (365) completed the questionnaire. The onset and frequency of most symptoms was similar to those reported in the literature in physician‐reported studies. Some were understudied or not typically associated with multiple system atrophy (MSA), including reduced female sexual sensation (55%), forgetfulness (60%), pseudobulbar affect (37%), olfactory changes (36%), and visual hallucinations (21%). Conclusions Patient‐reported studies and ancillary online questionnaires are valid, underused research tools useful to advance our knowledge on understudied MSA features and highlight the patients' voice.

show abstract

Section: Discussionmentioning

confidence: 98%

Patient‐Reported Symptoms in the Global Multiple System Atrophy Registry

Palma

Krismer

Meissner

et al. 2022

Movement Disord Clin Pract

View full text Add to dashboard Cite

show abstract

“…In a recent report reviewing clinical symptoms before MSA diagnosis using a sizable medical database [ 30 ], hypotension, urinary disturbance, dizziness, and disequilibrium were more frequent. Additionally, the importance of new-onset or exacerbated snoring has also been noted [ 31 ].…”

Section: Other Early Clinical Phenotypes and Featuresmentioning

confidence: 99%

Multiple System Atrophy: Advances in Diagnosis and Therapy

Watanabe

Shima

Mizutani

et al. 2023

JMD

View full text Add to dashboard Cite

This review summarizes improvements in understanding the pathophysiology and early clinical symptoms of multiple system atrophy (MSA) and advancements in diagnostic methods and disease-modifying therapies for the condition. In 2022, the Movement Disorder Society proposed new diagnostic criteria to develop disease-modifying therapies and promote clinical trials of MSA since the second consensus was proposed in 2008. Regarding pathogenesis, cutting-edge findings have accumulated on the interactions of α-synuclein, neuroinflammation, and oligodendroglia with neurons. In neuroimaging, introducing artificial intelligence, machine learning, and deep learning has notably improved diagnostic accuracy and individual analyses. Advancements in treatment have also been achieved, including immunotherapy therapy against α-synuclein and serotonin-targeted and mesenchymal stem cell therapies, which are thought to affect several aspects of the disease, including neuroinflammation. The accelerated progress in clarifying the pathogenesis of MSA over the past few years and the development of diagnostic techniques for detecting early-stage MSA are expected to facilitate the development of disease-modifying therapies for one of the most intractable neurodegenerative diseases.

show abstract

“…Correspondingly, evidence notes that depression is a strong predictor of physical illness and early death in neurological diseases ( 18 ). However, it is not known whether depression is a part of the disease spectrum or is secondary to the severity of motor or autonomic impairment in MSA patients ( 19 , 20 ). It is also unclear whether the occurrence of depression in MSA has its own particularity when compared to other neurological diseases.…”

Section: Introductionmentioning

confidence: 99%

Depression in multiple system atrophy: Views on pathological, clinical and imaging aspects

Pan

Chen

et al. 2022

Front. Psychiatry

View full text Add to dashboard Cite

Multiple system atrophy (MSA) is a common atypical parkinsonism, characterized by a varying combination of autonomic, cerebellar, and pyramidal systems. It has been noticed that the patients with MSA can be accompanied by some neuropsychiatric disorders, in particular depression. However, there is limited understanding of MSA-related depression. To bridge existing gaps, we summarized research progress on this topic and provided a new perspective regarding pathological, clinical, and imaging aspects. Firstly, we synthesized corresponding studies in order to investigate the relationship between depression and MSA from a pathological perspective. And then, from a clinical perspective, we focused on the prevalence of depression in MS patients and the comparison with other populations. Furthermore, the associations between depression and some clinical characteristics, such as life quality and gender, have been reported. The available neuroimaging studies were too sparse to draw conclusions about the radiological aspect of depression in MSA patients but we still described them in the presence of paper. Finally, we discussed some limitations and shortcomings existing in the included studies, which call for more high-quality basic research and clinical research in this field.

show abstract

Pre-diagnostic presentations of Multiple System Atrophy case control study in a primary care dataset

Cited by 10 publications

References 12 publications

Patient‐Reported Symptoms in the Global Multiple System Atrophy Registry

Patient‐Reported Symptoms in the Global Multiple System Atrophy Registry

Multiple System Atrophy: Advances in Diagnosis and Therapy

Depression in multiple system atrophy: Views on pathological, clinical and imaging aspects

Contact Info

Product

Resources

About